Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. - Suppr | 超能文献

Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.

作者信息

Lo A, Stratta R J, Alloway R R, Egidi M F, Shokouh-Amiri M H, Grewal H P, Gaber A O

机构信息

Department of Pharmacy, University of Tennessee-Memphis, Memphis, Tennessee, USA.

出版信息

Transplant Proc. 2001 Feb-Mar;33(1-2):1701-3. doi: 10.1016/s0041-1345(00)02649-x.

DOI:10.1016/s0041-1345(00)02649-x

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.

Transplant Proc. 2001 Feb-Mar;33(1-2):1701-3. doi: 10.1016/s0041-1345(00)02649-x.

2

Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.对于使用他克莫司、霉酚酸酯和类固醇作为维持性免疫抑制的原发性肾移植受者，使用达利珠单抗进行诱导治疗。

Transplant Proc. 2001 Feb-Mar;33(1-2):1013-4. doi: 10.1016/s0041-1345(00)02309-5.

3

Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.肾移植中新型免疫抑制方案的临床疗效与成本效益：一项系统评价与模型研究

Health Technol Assess. 2005 May;9(21):1-179, iii-iv. doi: 10.3310/hta9210.

4

A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.一项多中心、开放标签、比较两种达利珠单抗给药策略与不使用抗体诱导剂联合他克莫司、霉酚酸酯和类固醇预防同期肾胰腺移植受者急性排斥反应的试验：中期分析。

Clin Transplant. 2002 Feb;16(1):60-8. doi: 10.1034/j.1399-0012.2002.00108.x.

5

The role of newer monoclonal antibodies in renal transplantation.新型单克隆抗体在肾移植中的作用。

Transplant Proc. 2001 Feb-Mar;33(1-2):1000-1. doi: 10.1016/s0041-1345(00)02303-4.

6

Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.达利珠单抗诱导治疗联合他克莫司、霉酚酸酯和类固醇作为维持性免疫抑制方案用于原发性肾移植受者的疗效与安全性。

Transplant Proc. 2003 Mar;35(2):873-4. doi: 10.1016/s0041-1345(02)04035-6.

7

Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.白细胞介素-2受体拮抗剂在预防活体供体移植急性排斥反应中的应用

Transplant Proc. 2001 Nov-Dec;33(7-8):3203-4. doi: 10.1016/s0041-1345(01)02363-6.

8

Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous [correction of simultaneus] pancreas-kidney transplantation: analysis of early outcome.

Transplant Proc. 2002 Aug;34(5):1909-10. doi: 10.1016/s0041-1345(02)03119-6.

9

Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.巴利昔单抗与达利珠单抗联合三联免疫抑制治疗在尸体供肾移植中的前瞻性随机研究。

Transplantation. 2010 Apr 27;89(8):1022-7. doi: 10.1097/TP.0b013e3181d02496.

10

The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.使用抗CD25单克隆抗体和霉酚酸酯可使肾移植受者使用低剂量他克莫司并早期停用类固醇。

Clin Transplant. 2003 Jun;17(3):234-41. doi: 10.1034/j.1399-0012.2003.00038.x.

引用本文的文献

1

A prospective comparison of simultaneous kidney-pancreas transplantation with systemic-enteric versus portal-enteric drainage.同期肾胰联合移植采用系统-肠内引流与门静脉-肠内引流的前瞻性比较。

Ann Surg. 2001 Jun;233(6):740-51. doi: 10.1097/00000658-200106000-00003.